Fed. Circ. Revives Patents In IP Suit Over Opioid Generic

By Jasmin Boyce ( December 21, 2022, 6:35 PM EST) -- The Federal Circuit partly reversed a lower court decision Wednesday regarding the validity of three BioDelivery Sciences patents asserted against Alvogen in litigation over the opioid drug Belbuca, determining that the district judge applied the wrong evidentiary standards when invalidating claims in two of the patents....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!